Консенсус по лечению больных псевдомиксомой брюшины

Введение: Лечение больных псевдомиксомой брюшины — одна из сложных и нерешенных проблем в онкологии. В отечественной медицинской литературе тема псевдомиксомы брюшины представлена единичными разрозненными публикациями. В основных зарубежных национальных клинических руководствах данная тема также не освещена. Основными документами, определяющими подходы к лечению псевдомиксомы брюшины, являются национальные консенсусы. Настоящий Консенсус является первой попыткой предложить стандартизованные подходы к проблеме псевдомиксомы брюшины в России.

Методы: Настоящий Консенсус принят на основании анализа литературных данных, анализа известных зарубежных консенсусов, а также в результате серии обсуждений с участием специалистов, имеющих значительный личный опыт в диагностике и лечении псевдомиксомы брюшины.

Результаты: Итоговый документ Консенсуса представлен в формате расширенных клинических рекомендаций, освещающих все аспекты данной патологии — эпидемиологию, патогенез, классификацию, клиническую картину, диагностику, и возможные варианты лечения, наблюдение после лечения и организационные вопросы.

Заключение: Настоящий Консенсус создан с целью предложить практикующим врачам оптимальную стратегию лечения псевдомиксомы брюшины, а также информировать врачей (как онкологов, так и общего профиля) об особенностях данной редкой патологии.

1. Sugarbaker P.H. Are there curative options to peritoneal carcinomatosis?. Ann Surg 2005;242(5):748–751. https://doi.org/10.1097/00000658-200511000-00023

2. Smeenk R.M., van Velthuysen M.L., Verwaal V.J., Zoetmulder F.A. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201. https://doi.org/10.1016/j.ejso.2007.04.002

3. Sugarbaker P.H. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7(1):69–76. https://doi.org/10.1016/S1470-2045(05)70539-8

4. Циторедуктивная хирургия и периоперационная химиотерапия для лечения опухолей с перитонеальной диссеминаций. Руководство и видеоатлас. Второе издание. Под редакцией Пол Шугабейкер, главный редактор русскоязычного издания Вадим Гущин 2019.

5. Govaerts K., Lurvink R.J., De Hingh IHJ.T., et al. Appendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol 2021;47(1):11–35. https://doi.org/10.1016/j.ejso.2020.02.012

6. Chicago Consensus Working Group. The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases. Ann Surg Oncol 2020;27(6):1761–1767. https://doi.org/10.1245/s10434-020-08315-x

7. WHO Classification of Tumours Editorial Board. Digestive system tumours (5th edition). – IARC; Lyon, 2019:35–155.

8. Carr N.J., Cecil T.D., Mohamed F., et al. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol 2016;40(1):14–26.9. https://doi.org/10.1097/PAS.0000000000000535

9. AJCC Staging https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/ajcc-staging-online/

10. Umetsu S.E., Kakar S. Staging of appendiceal mucinous neoplasms: challenges and recent updates. Hum Pathol 2023;132:65–76. https://doi.org/10.1016/j.humpath.2022.07.004

11. National Comprehensive Cancer Network v.5.2024 https://www.nccn.org/guidelines/guidelines-detail?category = 1&id = 1428

12. Carmignani C.P., Hampton R., Sugarbaker C.E., et al. Utility of CEA and CA 19–9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. J Surg Oncol 2004;87(4):162–166. https://doi.org/10.1002/jso.20107

13. Munoz-Zuluaga C.A., King M.C., Diaz-Sarmiento V.S., et al. Defining “Complete Cytoreduction» After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis. Ann Surg Oncol 2020 Dec;27(13):5026–5036. doi: 10.1245/s10434-020-08844-5, PMID: 32705513.

14. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–2456. https://doi.org/10.1200/JCO.2011.39.7166

15. Nikiforchin A., Sardi A., King MC., et al. Safety of Nephrectomy Performed During CRS/HIPEC: A Propensity Score-Matched Study. Ann Surg Oncol 2023;30(4):2520–2528. https://doi.org/10.1245/s10434-022-12862-w

16. Glehen O., Mohamed F., Sugarbaker P.H. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004 Aug;240(2):278–85. https://doi.org/10.1097/01.sla.0000133183.15705.71

17. Baratti D., Kusamura S., Nonaka D., et al. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2009;249(2):243–249. https://doi.org/10.1097/SLA.0b013e31818eec64

18. Somashekhar S.P., Rohit K.C., Ramya Y., et al. Bowel Anastomosis After or Before HIPEC: A Comparative Study in Patients Undergoing CRS + HIPEC for Peritoneal Surface Malignancy. Ann Surg Oncol 2022 Jan;29(1):214–223. https://doi.org/10.1245/s10434-021-10661-3

19. Hübner M., Kusamura S., Villeneuve L., et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management. Eur J Surg Oncol 2020;46(12):2292–2310. https://doi.org/10.1016/j.ejso.2020.07.041

20. Hübner M., Kusamura S., Villeneuve L., et al. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part II: Preoperative and intraoperative management. Eur J Surg Oncol 2020;46(12):2311–2323. https://doi.org/10.1016/j.ejso.2020.08.006

21. Solanki S.L., Mukherjee S., Agarwal V., et al. Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Indian J Anaesth 2019;63(12):972–987. https://doi.org/10.4103/ija.IJA_765_19

22. Lopez-Ramirez F., Gushchin V., Sittig M., et al. Iterative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol 2022;29(6):3390–3401. https://doi.org/10.1245/s10434-021-11233-1

23. Bhutiani N., Grotz T.E., Concors S.J., et al. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol 2024;31(1):614–621. https://doi.org/1010.1245/s10434-023-14422-2

24. Blackham A.U., Swett K., Eng C., et al. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2014;109(7):740–745. https://doi.org/10.1002/jso.23547

25. Asare E.A., Compton C.C., Hanna N.N., et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer 2016;122(2):213–221. https://doi.org/10.1002/cncr.29744

26. Milovanov V., Sardi A., Ledakis P., et al. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). Eur J Surg Oncol 2015;41(5):707–712. https://doi.org/10.1016/j.ejso.2015.01.005

27. Pietrantonio F., Maggi C., Fanetti G., et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist 2014;19(8):845–850. https://doi.org/10.1634/theoncologist.2014-0106

28. Baron E., Sardi A., King M.C., et al. Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol 2023;49(1):179–187. https://doi.org/10.1016/j.ejso.2022.08.022

29. Tejani M.A., ter Veer A., Milne D., et al. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Canc Netw 2014;12(8):1123–1130. https://doi.org/10.6004/jnccn.2014.0109

30. Baron E., King M.C., Gushchin V., et al. ASO Author Reflections: CRS/HIPEC Cannot be Done-Now what? Systemic Chemotherapy in Mucinous Appendiceal Cancer. Ann Surg Oncol 2022;29(11):6590–6591. https://doi.org/10.1245/s10434-022-11925-2

31. Logan-Collins J.M., Lowy A.M., Robinson-Smith T.M., et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 2008;15(3):738–744. https://doi.org/10.1245/s10434-007-9699-7

32. Choe J.H., Overman M.J., Fournier K.F., et al. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol 2015;22(8):2578–2584. https://doi.org/10.1245/s10434-014-4335-9

33. Franke A.J., Iqbal A., Starr J., et al. Management of malignant bowel obstruction associated with gi cancers. J Oncol Pract 2017;13(7):426–434. https://doi.org/10.1200/jop.2017.022210.